Quin Wills

As Founder and CEO of Ochre, previously CSO, Quin has been driving the company's innovative approach to late-stage liver disease – developing potential new therapeutics to target disease progression. Quin will now lead the company in the next phase of its ambitions: progressing new drug candidates towards the clinic. Quin has dedicated his life’s work to finding breakthrough treatments for late stage liver disease. With his medical training, and degrees in genetics and mathematics from Oxford and Cambridge Universities, Quin founded his first drug discovery company in liver genomics 20 years ago. He’s since made significant steps in researching the genetic drivers of chronic liver disease and pioneering novel treatments.